Filter by
Filter by
Initial toxicity, QoL outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated vs. standard fractionated PT for low-risk prostate cancer
A multi-center prospective phase 3 randomized trial aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and...
Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes.
A study by the Seattle group analyzed 231 patients of localized prostate cancer treated with protons. Median follow-up was 1.7 years. Grade 3 toxicity was seen...
Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
A retrospective analysis on 100 patients' acute and late genitourinary (GU) and gastrointestinal (GI) toxicities associated with post-prostatectomy proton...
Minimal toxicity after PBT for prostate and pelvic nodal irradiationresults, proton collaborative group REG001-09 trial.
This PCG study evaluated toxicity outcomes for non-metastatic prostate cancer patients who received pelvic radiation therapy.
The study demonstrated PBT...
Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer.
A study reported toxicity of 526 localized prostate cancer patients treated with proton therapy and demonstrated the safety of HFPT for localized PCa patients...
Biochemical Results, Toxicity, Patient QoL After Delivery of Dose-Escalated Image Guided PT for Prostate Cancer
A large series of 1327 localized prostate cancer patients reported 5-year biochemical control rate, toxicity and patient-reported quality of life after proton...